Clinical Detection, Risk Factors, and Cardiovascular Consequences of Medial Arterial Calcification: A Pattern of Vascular Injury Associated With Aberrant Mineral Metabolism

Seminars in Nephrology

Volumn 33, Issue 2, 2013, Pages 93-105

  Lau, Wei Ling ^a,b   Ix, Joachim H ^c,d,e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

atherosclerosis; chronic kidney disease; medial arterial calcification; Vascular calcification

Indexed keywords

ELASTIN; PHOSPHORUS; WARFARIN;

ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; HOMEOSTASIS; HUMAN; KIDNEY FAILURE; MEDIAL ARTERIAL CALCIFICATION; MINERAL METABOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN DEGRADATION; RISK FACTOR; THROMBOEMBOLISM;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MONCKEBERG MEDIAL CALCIFIC SCLEROSIS; PHOSPHORUS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 84875271197     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.12.011     Document Type: Article

References (152)

1. Lindner A., Charra B., Sherrard D.J., Scribner B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974, 290:697-701.
2. Goodman W.G., Goldin J., Kuizon B.D., Yoon C., Gales B., Sider D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342:1478-1483.
3. US Renal Data System, USRDS 2011 annual data report 2011, USRDS, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
4. Keith D.S., Nichols G.A., Gullion C.M., Brown J.B., Smith D.H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663.
5. Monckeberg J. Uber die reine mediaverkalkung der extremitatenarterien und ihr verhalten zur arteriosklerose. Virchows Arch Pathol Anat 1902, 171:141-167.
6. Lindbom A. Arterioclsoeriss and arterial thrombosis in the lower limb. A roentgenological study. Acta Radiol 1950, 80:1-80.
7. Lin T.C., Tintut Y., Lyman A., Mack W., Demer L.L., Hsiai T.K. Mechanical response of a calcified plaque model to fluid shear force. Ann Biomed Eng 2006, 34:1535-1541.
8. Richardson P.D., Davies M.J., Born G.V. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989, 2:941-944.
9. Reant P., Brunot S., Lafitte S., Serri K., Leroux L., Corneloup O., et al. Predictive value of noninvasive coronary angiography with multidetector computed tomography to detect significant coronary stenosis before valve surgery. Am J Cardiol 2006, 97:1506-1510.
10. Blacher J., Guerin A.P., Pannier B., Marchais S.J., London G.M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001, 38:938-942.
11. Block G.A., Raggi P., Bellasi A., Kooienga L., Spiegel D.M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007, 71:438-441.
12. Detrano R., Guerci A.D., Carr J.J., Bild D.E., Burke G., Folsom A.R., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008, 358:1336-1345.
13. London G.M., Marchais S.J., Guerin A.P., Metivier F., Adda H. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 2002, 17:1713-1724.
14. Niederhoffer N., Lartaud-Idjouadiene I., Giummelly P., Duvivier C., Peslin R., Atkinson J. Calcification of medial elastic fibers and aortic elasticity. Hypertension 1997, 29:999-1006.
15. Amann K., Neususs R., Ritz E., Irzyniec T., Wiest G., Mall G. Changes of vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens 1995, 8:409-417.
16. Amann K., Tornig J., Flechtenmacher C., Nabokov A., Mall G., Ritz E. Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia: evidence for a permissive action of PTH. Nephrol Dial Transplant 1995, 10:2043-2048.
17. Amann K., Wolf B., Nichols C., Tornig J., Schwarz U., Zeier M., et al. Aortic changes in experimental renal failure: hyperplasia or hypertrophy of smooth muscle cells?. Hypertension 1997, 29:770-775.
18. Levy B.I., Benessiano J., Poitevin P., Safar M.E. Endothelium-dependent mechanical properties of the carotid artery in WKY and SHR. Role of angiotensin converting enzyme inhibition. Circ Res 1990, 66:321-328.
19. Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 2008, 3:1599-1605.
20. Micheletti R.G., Fishbein G.A., Currier J.S., Fishbein M.C. Monckeberg sclerosis revisited: a clarification of the histologic definition of Monckeberg sclerosis. Arch Pathol Lab Med 2008, 132:43-47.
21. Schlieper G., Aretz A., Verberckmoes S.C., Krüger T., Behets G.J., Ghadimi R., et al. Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol 2010, 21:689-696.
22. Becker A., Epple M., Müller K.M., Schmitz I. A comparative study of clinically well-characterized human atherosclerotic plaques with histological, chemical, and ultrastructural methods. J Inorg Biochem 2004, 98:2032-2038.
23. Schwarz U., Buzello M., Ritz E., Stein G., Raabe G., Wiest G., et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000, 15:218-223.
24. Gross M.L., Meyer H.P., Ziebart H., Rieger P., Wenzel U., Amann K., et al. Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol 2007, 2:121-134.
25. Drueke T.B. Arterial intima and media calcification: distinct entities with different pathogenesis or all the same?. Clin J Am Soc Nephrol 2008, 3:1583-1584.
26. Block G., Hulbert-Shearon T., Levin N., Port F. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998, 31:607-617.
27. Adeney K.L., Siscovick D.S., Ix J.H., Seliger S.L., Shlipak M.G., Jenny N.S., et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009, 20:381-387.
28. Dhingra R., Sullivan L., Fox C., Wang T., D'Agostino R.S., Gaziano J., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007, 167:879-885.
29. Tonelli M., Curhan G., Pfeffer M., Sacks F., Thadhani R., Melamed M.L., et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 2009, 120:1784-1792.
30. Kestenbaum B., Sampson J., Rudser K., Patterson D., Seliger S., Young B., et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005, 16:520-528.
31. Tonelli M., Sacks F., Pfeffer M., Gao Z., Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005, 112:2627-2633.
32. Faul C., Amaral A.P., Oskouei B., Hu M.C., Sloan A., Isakova T., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
33. Parker B.D., Schurgers L.J., Brandenburg V.M., Christenson R.H., Vermeer C., Ketteler M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010, 152:640-648.
34. Dhingra R., Gona P., Benjamin E.J., Wang T.J., Aragam J., D'Agostino R.B., et al. Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community. Eur J Heart Fail 2010, 12:812-818.
35. Dhingra R., Sullivan L.M., Fox C.S., Wang T.J., D'Agostino R.B., Gaziano J.M., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007, 167:879-885.
36. Foley R.N., Collins A.J., Ishani A., Kalra P.A. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2008, 156:556-563.
37. Saab G., Whooley M.A., Schiller N.B., Ix J.H. Association of serum phosphorus with left ventricular mass in men and women with stable cardiovascular disease: data from the Heart and Soul Study. Am J Kidney Dis 2010, 56:496-505.
38. Kestenbaum B., Katz R., de Boer I., Hoofnagle A., Sarnak M.J., Shlipak M.G., et al. Vitamin d, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol 2011, 58:1433-1441.
39. Ix J.H., Katz R., Kestenbaum B., de Boer I.H., Chonchol M., Mukamal K.J., et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: the Cardiovascular Health Study. J Am Coll Cardiol 2012, 60:200-207.
40. Hruska K., Mathew S., Lund R., Qiu P., Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008, 74:148-157.
41. Marks J., Debnam E.S., Unwin R.J. Phosphate homeostasis and the renal-gastrointestinal axis. Am J Physiol Renal Physiol 2010, 299:F285-F296.
42. Gattineni J., Bates C., Twombley K., Dwarakanath V., Robinson M.L., Goetz R., et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009, 297:F282-F291.
43. Segawa H., Yamanaka S., Ito M., Kuwahata M., Shono M., Yamamoto T., et al. Internalization of renal type IIc Na-Pi cotransporter in response to a high-phosphate diet. Am J Physiol Renal Physiol 2005, 288:F587-F596.
44. Segawa H., Yamanaka S., Onitsuka A., Tomoe Y., Kuwahata M., Ito M., et al. Parathyroid hormone-dependent endocytosis of renal type IIc Na-Pi cotransporter. Am J Physiol Renal Physiol 2007, 292:F395-F403.
45. Hu M.C., Shi M., Zhang J., Pastor J., Nakatani T., Lanske B., et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010, 24:3438-3450.
46. Isakova T., Wahl P., Vargas G.S., Gutiérrez O.M., Scialla J., Xie H., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011, 79:1370-1378.
47. Hu M.C., Shi M., Zhang J., Quiñones H., Griffith C., Kuro-o M., et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011, 22:124-136.
48. Perwad F., Zhang M.Y., Tenenhouse H.S., Portale A.A. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007, 293:F1577-F1583.
49. Levin A., Bakris G., Molitch M., Smulders M., Tian J., Williams L., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71:31-38.
50. Block G., Cunningham J. Morbidity and mortality associated with abnormalities in bone and mineral metabolism in CKD. Clinical guide to the basics of bone and mineral metabolism in CKD 2006, National Kidney Foundation, New York, 7792. K. Olgaard (Ed.).
51. Shanahan C., Weissberg P., Metcalfe J. Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. Circ Res 1993, 73:193-204.
52. Jono S., McKee M., Murry C., Shioi A., Nishizawa Y., Mori K., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000, 87:E10-E17.
53. Steitz S., Speer M., Curinga G., Yang H., Haynes P., Aebersold R., et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001, 89:1147-1154.
54. Wada T., McKee M., Steitz S., Giachelli C. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999, 84:166-178.
55. Reynolds J., Joannides A., Skepper J., McNair R., Schurgers L., Proudfoot D., et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004, 15:2857-2867.
56. Shroff R., McNair R., Figg N., Skepper J., Schurgers L., Gupta A., et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008, 118:1748-1757.
57. Kaden J., Bickelhaupt S., Grobholz R., Vahl C., Hagl S., Brueckmann M., et al. Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 2004, 13:560-566.
58. Tyson K., Reynolds J., McNair R., Zhang Q., Weissberg P., Shanahan C. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003, 23:489-494.
59. Pai A., Leaf E.M., El-Abbadi M., Giachelli C.M. Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am J Pathol 2011, 178:764-773.
60. Li X., Yang H., Giachelli C. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006, 98:905-912.
61. Shroff R., McNair R., Skepper J., Figg N., Schurgers L., Deanfield J., et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010, 21:103-112.
62. Schlieper G., Aretz A., Verberckmoes S., Krüger T., Behets G., Ghadimi R., et al. Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol 2010, 21:689-696.
63. Navaneethan S.D., Schold J.D., Arrigain S., Jolly S.E., Jain A., Schreiber M.J., et al. Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. Am J Kidney Dis 2011, 58:536-543.
64. Tentori F., Hunt W.C., Stidley C.A., Rohrscheib M.R., Bedrick E.J., Meyer K.B., et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006, 70:1858-1865.
65. Teng M., Wolf M., Ofsthun M.N., Lazarus J.M., Hernán M.A., Camargo C.A., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005, 16:1115-1125.
66. Shoben A.B., Rudser K.D., de Boer I.H., Young B., Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008, 19:1613-1619.
67. Naves-Díaz M., Alvarez-Hernández D., Passlick-Deetjen J., Guinsburg A., Marelli C., Rodriguez-Puyol D., et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008, 74:1070-1078.
68. Davies M., Lund R., Mathew S., Hruska K. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 2005, 16:917-928.
69. González E.A., Lund R.J., Martin K.J., McCartney J.E., Tondravi M.M., Sampath T.K., et al. Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. Kidney Int 2002, 61:1322-1331.
70. Massy Z.A., Ivanovski O., Nguyen-Khoa T., Angulo J., Szumilak D., Mothu N., et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 2005, 16:109-116.
71. Davies M.R., Lund R.J., Hruska K.A. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 2003, 14:1559-1567.
72. Sarnak M.J., Levey A.S. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000, 35(Suppl 1):S117-S131.
73. Stenvinkel P., Heimbürger O., Lindholm B., Kaysen G.A., Bergström J. Are there two types of malnutrition in chronic renal failure?. Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000, 15:953-960.
74. Moody W.E., Edwards N.C., Madhani M., Chue C.D., Steeds R.P., Ferro C.J., et al. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association?. Atherosclerosis 2012, 223:86-94.
75. Endemann D.H., Schiffrin E.L. Endothelial dysfunction. J Am Soc Nephrol 2004, 15:1983-1992.
76. Swaminathan S., Shah S.V. Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease. Kidney Int 2011, 80:453-463.
77. Libby P., Okamoto Y., Rocha V.Z., Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010, 74:213-220.
78. Cheung A.K., Sarnak M.J., Yan G., Dwyer J.T., Heyka R.J., Rocco M.V., et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000, 58:353-362.
79. Stenvinkel P., Pecoits-Filho R., Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003, 14:1927-1939.
80. Yeun J.Y., Levine R.A., Mantadilok V., Kaysen G.A. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000, 35:469-476.
81. Wang A.Y., Lam C.W., Wang M., Chan I.H., Yu C.M., Lui S.F., et al. Increased circulating inflammatory proteins predict a worse prognosis with valvular calcification in end-stage renal disease: a prospective cohort study. Am J Nephrol 2008, 28:647-653.
82. Sester U., Sester M., Heine G., Kaul H., Girndt M., Köhler H. Strong depletion of CD14(+)CD16(+) monocytes during haemodialysis treatment. Nephrol Dial Transplant 2001, 16:1402-1408.
83. Girndt M., Sester M., Sester U., Kaul H., Köhler H. Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl 2001, 78:S206-S211.
84. Witkowski J.M., Soroczyńska-Cybula M., Bryl E., Smoleńska Z., JǒŸwik A. Klotho-a common link in physiological and rheumatoid arthritis-related aging of human CD4+ lymphocytes. J Immunol 2007, 178:771-777.
85. Betjes M.G., Huisman M., Weimar W., Litjens N.H. Expansion of cytolytic CD4+CD28- T cells in end-stage renal disease. Kidney Int 2008, 74:760-767.
86. Naik V., Leaf E.M., Hu J.H., Yang H.Y., Nguyen N.B., Giachelli C.M., et al. Sources of cells that contribute to atherosclerotic intimal calcification: an in vivo genetic fate mapping study. Cardiovasc Res 2012, 94:545-554.
87. Tintut Y., Patel J., Parhami F., Demer L.L. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000, 102:2636-2642.
88. Byon C.H., Javed A., Dai Q., Kappes J.C., Clemens T.L., Darley-Usmar V.M., et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem 2008, 283:15319-15327.
89. Sandberg E.M., Sayeski P.P. Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells. J Biol Chem 2004, 279:34547-34552.
90. Schaeffer C., Thomassin L., Rochette L., Connat J.L. Apoptosis induced in vascular smooth muscle cells by oxidative stress is partly prevented by pretreatment with CGRP. Ann N Y Acad Sci 2003, 1010:733-737.
91. Fritze O., Romero B., Schleicher M., Jacob M.P., Oh D.Y., Starcher B., et al. Age-related changes in the elastic tissue of the human aorta. J Vasc Res 2012, 49:77-86.
92. Fonck E., Feigl G.G., Fasel J., Sage D., Unser M., Rüfenacht D.A., et al. Effect of aging on elastin functionality in human cerebral arteries. Stroke 2009, 40:2552-2556.
93. Chung A., Yang H., Kim J., Sigrist M., Chum E., Gourlay W., et al. Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease. Circulation 2009, 120:792-801.
94. Smith E.R., Tomlinson L.A., Ford M.L., McMahon L.P., Rajkumar C., Holt S.G. Elastin degradation is associated with progressive aortic stiffening and all-cause mortality in predialysis chronic kidney disease. Hypertension 2012, 59:973-978.
95. Rucker R. Calcium binding to elastin. Adv Exp Med Biol 1974, 48:185-209.
96. Simionescu A., Philips K., Vyavahare N. Elastin-derived peptides and TGF-beta1 induce osteogenic responses in smooth muscle cells. Biochem Biophys Res Commun 2005, 334:524-532.
97. Hosaka N., Mizobuchi M., Ogata H., Kumata C., Kondo F., Koiwa F., et al. Elastin degradation accelerates phosphate-induced mineralization of vascular smooth muscle cells. Calcif Tissue Int 2009, 85:523-529.
98. Sukhova G.K., Zhang Y., Pan J.H., Wada Y., Yamamoto T., Naito M., et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003, 111:897-906.
99. Aikawa E., Aikawa M., Libby P., Figueiredo J.L., Rusanescu G., Iwamoto Y., et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 2009, 119:1785-1794.
100. Shanahan C.M., Cary N.R., Metcalfe J.C., Weissberg P.L. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994, 93:2393-2402.
101. Spronk H., Soute B., Schurgers L., Cleutjens J., Thijssen H., De Mey J., et al. Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun 2001, 289:485-490.
102. Murshed M., Schinke T., McKee M., Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004, 165:625-630.
103. Parker B.D., Ix J.H., Cranenburg E.C., Vermeer C., Whooley M.A., Schurgers L.J. Association of kidney function and uncarboxylated matrix Gla protein: data from the Heart and Soul Study. Nephrol Dial Transplant 2009, 24:2095-2101.
104. Schlieper G., Westenfeld R., Krüger T., Cranenburg E.C., Magdeleyns E.J., Brandenburg V.M., et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 2011, 22:387-395.
105. Lomashvili K.A., Khawandi W., O'Neill W.C. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005, 16:2495-2500.
106. O'Neill W.C., Sigrist M.K., McIntyre C.W. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2010, 25:187-191.
107. Schinke T., Amendt C., Trindl A., Pöschke O., Müller-Esterl W., Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996, 271:20789-20796.
108. Heiss A., Eckert T., Aretz A., Richtering W., van Dorp W., Schäfer C., et al. Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles. J Biol Chem 2008, 283:14815-14825.
109. Moe S.M., Reslerova M., Ketteler M., O'Neill K., Duan D., Koczman J., et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005, 67:2295-2304.
110. Ketteler M., Bongartz P., Westenfeld R., Wildberger J.E., Mahnken A.H., Böhm R., et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003, 361:827-833.
111. Odamaki M., Shibata T., Takita T., Kumagai H. Serum fetuin-A and aortic calcification in hemodialysis patients. Kidney Int 2005, 68:2915. author reply, 2916.
112. Stenvinkel P., Wang K., Qureshi A.R., Axelsson J., Pecoits-Filho R., Gao P., et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005, 67:2383-2392.
113. Ix J.H., Barrett-Connor E., Wassel C.L., Cummins K., Bergstrom J., Daniels L.B., et al. The association of fetuin-A with subclinical cardiovascular disease in community-dwelling persons: the Rancho Bernardo Study. J Am Coll Cardiol 2011, 58:2372-2379.
114. Ix J.H., Katz R., de Boer I.H., Kestenbaum B.R., Peralta C.A., Jenny N.S., et al. Fetuin-A is inversely associated with coronary artery calcification in community-living persons: the Multi-Ethnic Study of Atherosclerosis. Clin Chem 2012, 58:887-895.
115. Laughlin G.A., Cummins K., Wassel C.L., Daniels L.B., Ix J.H. The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo Study. J Am Coll Cardiol 2012, 59:1688-1696.
116. Mehrotra R., Westenfeld R., Christenson P., Budoff M., Ipp E., Takasu J., et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005, 67:1070-1077.
117. Ix J.H., Chertow G.M., Shlipak M.G., Brandenburg V.M., Ketteler M., Whooley M.A. Fetuin-A and kidney function in persons with coronary artery disease-data from the Heart and Soul Study. Nephrol Dial Transplant 2006, 21:2144-2151.
118. Ix J.H., Wassel C.L., Kanaya A.M., Vittinghoff E., Johnson K.C., Koster A., et al. Fetuin-A and incident diabetes mellitus in older persons. JAMA 2008, 300:182-188.
119. Rauth G., Poschke O., Fink E., Eulitz M., Tippmer S., Kellerer M., et al. The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem 1992, 204:523-529.
120. Verduijn M., Prein R.A., Stenvinkel P., Carrero J.J., le Cessie S., Witasp A., et al. Is fetuin-A a mortality risk factor in dialysis patients or a mere risk marker?. A Mendelian randomization approach. Nephrol Dial Transplant 2011, 26:239-245.
121. Jensen M.K., Bartz T.M., Mukamal K.J., Djousse L., Kizer J., Tracy R., et al. Fetuin-A, diabetes, and risk of cardiovascular disease in older adults: the Cardiovascular Health Study. Diabetes Care 2012, In press.
122. Palaniswamy C., Sekhri A., Aronow W.S., Kalra A., Peterson S.J. Association of warfarin use with valvular and vascular calcification: a review. Clin Cardiol 2011, 34:74-81.
123. Bouvet C., Moreau S., Blanchette J., de Blois D., Moreau P. Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler Thromb Vasc Biol 2008, 28:856-862.
124. Verdalles Guzmán U., de la Cueva P., García de Vinuesa E., Verde S., Goicoechea M., Mosse A., et al. [Calciphylaxis: fatal complication of cardiometabolic syndrome in patients with end stage kidney disease]. Nefrologia 2008, 28:32-36.
125. Holden R.M., Sanfilippo A.S., Hopman W.M., Zimmerman D., Garland J.S., Morton A.R. Warfarin and aortic valve calcification in hemodialysis patients. J Nephrol 2007, 20:417-422.
126. Spiegel D.M., Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int 2012, 81:1116-1122.
127. London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003, 18:1731-1740.
128. Raggi P., Vukicevic S., Moysés R.M., Wesseling K., Spiegel D.M. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol 2010, 5(Suppl 1):S31-S40.
129. Navaneethan S., Palmer S., Craig J., Elder G., Strippoli G. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009, 54:619-637.
130. Costacou T., Huskey N.D., Edmundowicz D., Stolk R., Orchard T.J. Lower-extremity arterial calcification as a correlate of coronary artery calcification. Metabolism 2006, 55:1689-1696.
131. Everhart J.E., Pettitt D.J., Knowler W.C., Rose F.A., Bennett P.H. Medial arterial calcification and its association with mortality and complications of diabetes. Diabetologia 1988, 31:16-23.
132. Lehto S., Niskanen L., Suhonen M., Ronnemaa T., Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996, 16:978-983.
133. Du J., Hamilton G., Takahashi A., Bydder M., Chung C.B. Ultrashort echo time spectroscopic imaging (UTESI) of cortical bone. Magn Reson Med 2007, 58:1001-1009.
134. Du J., Corbeil J., Znamirowski R., Angle N., Peterson M., Bydder G.M., et al. Direct imaging and quantification of carotid plaque calcification. Magn Reson Med 2011, 65:1013-1020.
135. Duhn V., D'Orsi E.T., Johnson S., D'Orsi C.J., Adams A.L., O'Neill W.C. Breast arterial calcification: a marker of medial vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:377-382.
136. Lijmer J.G., Hunink M.G., van den Dungen J.J., Loonstra J., Smit A.J. ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Biol 1996, 22:391-398.
137. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006, 113:e463-e654.
138. Ix J.H., Criqui M.H. Epidemiology and diagnosis of peripheral arterial disease in patients with chronic kidney disease. Adv Chronic Kidney Dis 2008, 15:378-383.
139. Ix J.H., Miller R.G., Criqui M.H., Orchard T. Test characteristics of the ankle brachial index and ankle brachial difference for medial arterial calcification on lower limb x-ray in type 1 diabetes. J Vasc Surgery 2012, 56:721-727.
140. de Vinuesa S.G., Ortega M., Martinez P., Goicoechea M., Campdera F.G., Luno J. Subclinical peripheral arterial disease in patients with chronic kidney disease: prevalence and related risk factors. Kidney Int Suppl 2005, 93:S44-S47.
141. Young M.J., Adams J.E., Anderson G.F., Boulton A.J., Cavanagh P.R. Medial arterial calcification in the feet of diabetic patients and matched non-diabetic control subjects. Diabetologia 1993, 36:615-621.
142. Ix J.H., Katz R., De Boer I.H., Kestenbaum B.R., Allison M.A., Siscovick D.S., et al. Association of chronic kidney disease with the spectrum of ankle brachial index the CHS (Cardiovascular Health Study). J Am Coll Cardiol 2009, 54:1176-1184.
143. Criqui M.H., McClelland R.L., McDermott M.M., Allison M.A., Blumenthal R.S., Aboyans V., et al. The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010, 56:1506-1512.
144. Sutton-Tyrrell K., Venkitachalam L., Kanaya A.M., Boudreau R., Harris T., Thompson T., et al. Relationship of ankle blood pressures to cardiovascular events in older adults. Stroke 2008, 39:863-869.
145. Resnick H.E., Lindsay R.S., McDermott M.M., Devereux R.B., Jones K.L., Fabsitz R.R., et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004, 109:733-739.
146. Arain F.A., Ye Z., Bailey K.R., Chen Q., Liu G., Leibson C.L., et al. Survival in patients with poorly compressible leg arteries. J Am Coll Cardiol 2012, 59:400-407.
147. Ix J.H., De Boer I.H., Peralta C.A., Adeney K.L., Duprez D.A., Jenny N.S., et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009, 4:609-615.
148. Kendrick J., Ix J.H., Targher G., Smits G., Chonchol M. Relation of serum phosphorus levels to ankle brachial pressure index (from the Third National Health and Nutrition Examination Survey). Am J Cardiol 2010, 106:564-568.
149. Meng J., Wassel C.L., Kestenbaum B.R., Collins T.C., Criqui M.H., Lewis C.E., et al. Serum phosphorus levels and the spectrum of ankle-brachial index in older men: the Osteoporotic Fractures in Men (MrOS) study. Am J Epidemiol 2010, 171:909-916.
150. Ix J.H., Katz R., Peralta C.A., de Boer I.H., Allison M.A., Bluemke D.A., et al. A high ankle brachial index is associated with greater left ventricular mass MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010, 55:342-349.
151. O'Hare A.M., Katz R., Shlipak M.G., Cushman M., Newman A.B. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 2006, 113:388-393.
152. Wattanakit K., Folsom A.R., Duprez D.A., Weatherley B.D., Hirsch A.T. Clinical significance of a high ankle-brachial index: insights from the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 2007, 190:459-464.